October 22nd, 2010

Dabigatran Resource Round-Up

Our coverage of the FDA’s approval of dabigatran for the prevention of stroke and blood clots in patients with AF has triggered a flurry of comments from CardioExchange members, including questions about when dabigatran will be available, how much it will cost, who should — and shouldn’t — receive it, and what dosages should be prescribed. Check out our dabigatran round-up below and tell us what you think: All future dabigatran comments will reside here. Oh, and by the way, how do you pronounce dabigatran?

4 Responses to “Dabigatran Resource Round-Up”

  1. David Powell , md, facc says:

    Why withold for creat clearance 30 were enrolled in the trial. Furthermore, in a suprise move, the FDA approves 75 bid for clearance <30. As far as intracranial bleeding, there was a 70 % reduction on dabigatron. This seems to outweigh the absence of a specific reversal agent.!lo, the drug nearly always loses biologic effect in 12 to 18 hours.
    Indeed, the reduction in ICB and hemorrhagic stroke was consistent with both tested dabigatron doses, without evidence for an interaction with time in therapeutic range for warfarin. How motivating is this as an additional reason to switch patients from warfarin to dagigatron (even when they are" doing well" with warfarin)?


  3. William Pentz, MD says:

    It is not approved for this use, I would not be the first to try it for that indication!

  4. The risk of thromboembolism is higher with mechanical valves than atrial fibrillation. I’d want a study showing that dabigatran is as (or more) effective than coumadin in patients with mechanical valves before I recommended its use.